Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Craig C. Hofmeister, MD, David Siegel, MD, PhD, Sagar Lonial, MD, Jacob P. Laubach, MD, Yvonne A. Efebera, MD, David H. Vesole, MD, PhD, Ajay K. Nooka, MD, MPH, Jacalyn Rosenblatt, MD, MSc, Noopur Raje, MD., Mohamed H. Zaki, MD, PhD, Ye Hua, MD, MPH, Yan Li, PhD, Sheetal Shah, BA, Jianming Wang, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 1969.

https://doi.org/10.1182/blood.V122.21.1969.1969

Published: 2013

Journal Articles

STAT3 Inhibition Promotes Potent Th1 Responses By Down Regulating Pdl-1 Expression On Tumor Cells

Baldev Vasir, PhD, Hasan Rajabi, PhD, Heidi Mills, BA, Jacalyn Rosenblatt, MD, MSc, Dina Stroopinsky, PhD, Katarina Luptakova, MD, Maxwell D Coll, Palmer Kristen, Donald Kufe, MD, David Avigan, MD

Blood (2013) 122 (21): 3217.

https://doi.org/10.1182/blood.V122.21.3217.3217

Published: 2013

Journal Articles

Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential

Blood (2013) 122 (21): 127.

https://doi.org/10.1182/blood.V122.21.127.127

Published: 2013

Journal Articles

90 Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma

Katarina Luptakova, MD, Michelle Kim, Pamela Ely, MD, PhD, Barbara Grant, MD, John Anthony Parker, MD, PhD, Dimitrios Tzachanis, MD, PhD, Jacalyn Rosenblatt, MD, MSc, James Levine, MD, David Avigan, MD, Robin Joyce, MD

Blood (2010) 116 (21): 2866.

https://doi.org/10.1182/blood.V116.21.2866.2866

Published: 2010

Journal Articles

Prophylactic Rituximab After Allogeneic Stem Cell Transplantation Prevents Steroid-Requiring Chronic Graft-Vs.Host Disease

Corey Cutler, MD, MPH, FRCPC, Lixian Sun, MS, Haesook Kim, PhD, Stefanie Sarantopoulos, MD, PhD, Bhavjot Bindra, Yi-Bin Chen, MD, Jacalyn Rosenblatt, MD, MSc, Philippe Armand, MD, PhD, John Koreth, MBBS, DPhil, Vincent T. Ho, MD, Edwin P. Alyea, III, MD, Robert J. Soiffer, MD, Jerome Ritz, MD, Joseph H. Antin, MD

Blood (2010) 116 (21): 214.

https://doi.org/10.1182/blood.V116.21.214.214

Published: 2010

Journal Articles

Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition

Dina Stroopinsky, PhD, Jacalyn Rosenblatt, MD, MSc, Keisuke Ito, MD, PhD, Li Yin, Hasan Rajabi, PhD, Baldev Vasir, PhD, Turner Kufe, Brett Glotzbecker, MD, Katarina Luptakova, MD, Heidi Mills, BA, Robin Joyce, MD, Dimitrios Tzachanis, MD, PhD, Vassiliki A Boussiotis, MD, PhD, James Levine, MD, Ilene Galinsky, ANP, Richard Stone, MD, Pier Paolo Pandolfi, MD, PhD, Donald Kufe, MD, David Avigan, MD

Blood (2010) 116 (21): 848.

https://doi.org/10.1182/blood.V116.21.848.848

Published: 2010

Journal Articles

Lenalidomide Decreases PD-1 Expression, Depletes Regulatory T-Cells and Improves Cellular Response to a Multiple Myeloma/Dendritic Cell Fusion Vaccine In Vitro

Katarina Luptakova, MD, Brett Glotzbecker, MD, Heidi Mills, BA, Dina Stroopinsky, PhD, Baldev Vasir, PhD, Jacalyn Rosenblatt, MD, MSc, Donald Kufe, MD, David Avigan, MD

Blood (2010) 116 (21): 492.

https://doi.org/10.1182/blood.V116.21.492.492

Published: 2010

NARROW

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

STAT3 Inhibition Promotes Potent Th1 Responses By Down Regulating Pdl-1 Expression On Tumor Cells

Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential

90 Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma

Prophylactic Rituximab After Allogeneic Stem Cell Transplantation Prevents Steroid-Requiring Chronic Graft-Vs.Host Disease

Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition

Lenalidomide Decreases PD-1 Expression, Depletes Regulatory T-Cells and Improves Cellular Response to a Multiple Myeloma/Dendritic Cell Fusion Vaccine In Vitro

Email alerts

ASH Publications

American Society of Hematology

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

STAT3 Inhibition Promotes Potent Th1 Responses By Down Regulating Pdl-1 Expression On Tumor Cells

Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential

90 Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma

Prophylactic Rituximab After Allogeneic Stem Cell Transplantation Prevents Steroid-Requiring Chronic Graft-Vs.Host Disease

Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition

Lenalidomide Decreases PD-1 Expression, Depletes Regulatory T-Cells and Improves Cellular Response to a Multiple Myeloma/Dendritic Cell Fusion Vaccine In Vitro

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only